Product Description
Bayer is developing BAY-987534 as a treatment for Atopic Dermatitis. BAY-987534 is a modification of Bayer's Diprobase formulation. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03441568)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Unknown
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06747897 |
NCT06747897 | N/A |
Completed |
Dermatitis, Atopic |
2024-12-12 |
2025-01-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|